BioCentury | Sep 27, 2019
Product Development

Reading into the first wave of neoantigen results

The first clinical data from neoantigen vaccine companies have started to answer questions about the best way to quickly gauge whether patients are responding. The lessons include how to design combination trials that point to...
BC Week In Review | Dec 21, 2018
Company News

Amgen pulls out of Advaxis immunotherapy deal

Advaxis Inc. (NASDAQ:ADXS) will continue to enroll patients in a Phase I trial of its ADXS-NEO program despite Amgen Inc. (NASDAQ:AMGN) pulling out of a 2016 deal to develop the immunotherapy. Advaxis shares slid 37%...
BC Extra | Dec 14, 2018
Company News

Amgen pulls out of Advaxis immunotherapy deal

Advaxis Inc. (NASDAQ:ADXS) will continue to enroll patients in a Phase I trial of its ADXS-NEO program despite Amgen Inc. (NASDAQ:AMGN) pulling out of a 2016 deal to develop the immunotherapy. Advaxis shares slid 37%...
BC Innovations | Mar 16, 2017
Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
BC Extra | Aug 16, 2016
Financial News

Advaxis raises $30M in direct offering

Advaxis Inc. (NASDAQ:ADXS) raised $30 million through the sale of about 2.2 million shares at $13.50 in a registered direct offering with undisclosed institutional investors. The deal price is a 9% discount to Advaxis' close...
BioCentury | Aug 15, 2016
Product Development

No antigen left behind

Amgen Inc. partnered with Advaxis Inc. to develop a personalized neoantigen therapy platform with potential to invoke a broad immune response by both stimulating the immune system on multiple fronts and delivering the full repertoire...
BC Week In Review | Aug 8, 2016
Company News

Advaxis, Amgen deal

Advaxis granted Amgen exclusive, worldwide rights to develop and commercialize ADXS-NEO . Advaxis will receive $40 million up front. Advaxis is eligible for up to $475 million in milestones, plus high single- to mid- double-digit royalties....
BC Extra | Aug 2, 2016
Company News

Amgen licenses Advaxis' neoantigen therapy

Advaxis Inc. (NASDAQ:ADXS) jumped $2.61 (31%) to $11.08 on Tuesday after it granted Amgen Inc. (NASDAQ:AMGN) exclusive, worldwide rights to develop and commercialize ADXS-NEO, a patient-specific cancer immunotherapy that is expected to start clinical testing...
Items per page:
1 - 8 of 8